Intrapleural delivery of MSCs attenuates acute lung injury by paracrine/endocrine mechanism

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 11, 2012, Pages 2745-2753

  Qin, Zhao Hui ^a,e   Xu, Jin Fu ^b   Qu, Jie Ming ^a   Zhang, Jing ^a   Sai, Yin ^c   Chen, Chun Mei ^c   Wu, Lian ^d   Yu, Long ^c  

^a FUDAN UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Acute lung injury; Cell therapy; Lipopolysaccharides; Mesenchymal stem cells; Pleural cavity

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; CYTOKINE; ENDOTOXIN; INDOLE DERIVATIVE; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; PEROXIDASE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ANIMAL; ARTICLE; DRUG EFFECT; LUNG; LUNG LAVAGE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; METHODOLOGY; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT;

ACUTE LUNG INJURY; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; ENDOTOXINS; INDOLES; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; LUNG; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; PEROXIDASE; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 84868108562     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01597.x     Document Type: Article

References (36)

1. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005; 353: 1685-93.
2. Zambon M, Vincent JL. Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest. 2008; 133: 1120-7.
3. Erickson SE, Martin GS, Davis JL, et al. Recent trends in acute lung injury mortality: 1996-2005. Crit Care Med. 2009; 37: 1574-9.
4. Matthay MA. Treatment of acute lung injury: clinical and experimental studies. Proc Am Thorac Soc. 2008; 5: 297-9.
5. Xu J, Qu J, Cao L, et al. Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. J Pathol. 2008; 214: 472-81.
6. Song L, Xu JF, Qu JM, et al. A therapeutic role for mesenchymal stem cells in acute lung injury independent of hypoxia-induced mitogenic factor. J Cell Mol Med. 2012; 16: 376-85.
7. Gupta N, Su X, Popov B, et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol. 2007; 179: 1855-63.
8. Xu J, Woods CR, Mora AL, et al. Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. Am J Physiol Lung Cell Mol Physiol. 2007; 293: L131-41.
9. Mei SH, McCarter SD, Deng Y, et al. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med. 2007; 4: e269.
10. Zhao F, Zhang YF, Liu YG, et al. Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats. Transplant Proc. 2008; 40: 1700-5.
11. Rojas M, Xu J, Woods CR, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol. 2005; 33: 145-52.
12. Ortiz LA, Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA. 2007; 104: 11002-7.
13. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA. 2003; 100: 8407-11.
14. Beckett T, Loi R, Prenovitz R, et al. Acute lung injury with endotoxin or NO2 does not enhance development of airway epithelium from bone marrow. Mol Ther. 2005; 12: 680-6.
15. Kotton DN, Fabian AJ, Mulligan RC. Failure of bone marrow to reconstitute lung epithelium. Am J Respir Cell Mol Biol. 2005; 33: 328-34.
16. Chang JC, Summer R, Sun X, et al. Evidence that bone marrow cells do not contribute to the alveolar epithelium. Am J Respir Cell Mol Biol. 2005; 33: 335-42.
17. Loi R, Beckett T, Goncz KK, et al. Limited restoration of cystic fibrosis lung epithelium in vivo with adult bone marrow-derived cells. Am J Respir Crit Care Med. 2006; 173: 171-9.
18. Serikov VB, Popov B, Mikhailov VM, et al. Evidence of temporary airway epithelial repopulation and rare clonal formation by BM-derived cells following naphthalene injury in mice. Anat Rec (Hoboken). 2007; 290: 1033-45.
19. Lee JW, Fang X, Krasnodembskaya A, et al. Concise review: mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells. 2011; 29: 913-9.
20. Lee JW, Fang X, Gupta N, et al. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. PNAS. 2009; 106: 16357-62.
21. Matthay MA, Thompson BT, Read EJ, et al. Therapeutic potential of mesenchymal stem cells for severe acute lung injury. Chest. 2010; 138: 965-72.
22. Yang KY, Shih HC, How CK, et al. IV delivery of induced pluripotent stem cells attenuates endotoxin-induced acute lung injury in mice. Chest. 2011; 140: 1243-53.
23. Qin ZH, Qu J, Xu JF, et al. Intrapleural delivery of mesenchymal stem cells: a novel potential treatment for pleural diseases. Acta Pharmacol Sin. 2011; 32: 581-90.
24. Lee HS, Kim HJ, Moon CS, et al. Inhibition of c-Jun NH2-terminal kinase or extracellular signal-regulated kinase improves lung injury. Respir Res. 2004; 5: 23.
25. Takao Y, Mikawa K, Nishina K, et al. Attenuation of acute lung injury with propofol in endotoxemia. Anesth Analg. 2005; 100: 810-6.
26. Rojas M, Xu J, Woods CR, et al. Bone marrow derived mesenchymal stem cells in repair of the injured lung. Am J Resp Cell Mol Biol. 2005; 33: 145-52.
27. Krause DS, Theise ND, Collector MI, et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 2001; 105: 369-77.
28. Kotton DN, Ma BY, Cardoso MW, et al. Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development. 2001; 128: 5181-8.
29. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair - current views. Stem Cells. 2007; 25: 2896-902.
30. Horwitz EM, Prather WR. Cytokines as the major mechanism of mesenchymal stem cell clinical activity: expanding the spectrum of cell therapy. Isr Med Assoc J. 2009; 11: 209-11.
31. Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol. 2009; 217: 318-24.
32. Weiss DJ, Kolls JK, Ortiz LA, et al. Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc. 2008; 5: 637-67.
33. Krause DS. Bone marrow-derived cells and stem cells in lung repair. Proc Am Thorac Soc. 2008; 5: 323-7.
34. Iyer SS, Co C, Rojas M. Mesenchymal stem cells and inflammatory lung diseases. Panminerva Med. 2009; 51: 5-16.
35. Krause DS. Bone marrow-derived lung epithelial cells. Proc Am Thorac Soc. 2008; 5: 699-702.
36. Spitkovsky D, Hescheler J. Adult mesenchymal stromal stem cells for therapeutic applications. Minim Invasive Ther Allied Technol. 2008; 17: 79-90.